Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer von Herrera-Abreu, Maria Teresa, Palafox, Marta, Asghar, Uzma, Rivas, Martín A, Cutts, Rosalind J, Garcia-Murillas, Isaac, Pearson, Alex, Guzman, Marta, Rodriguez, Olga, Grueso, Judit, Bellet, Meritxell, Cortés, Javier, Elliott, Richard, Pancholi, Sunil, Baselga, José, Dowsett, Mitch, Martin, Lesley-Ann, Turner, Nicholas C, Serra, Violeta

Volltext

INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors von Li, Qing, Jiang, Baishan, Guo, Jiaye, Shao, Hong, Del Priore, Isabella S, Chang, Qing, Kudo, Rei, Li, Zhiqiang, Razavi, Pedram, Liu, Bo, Boghossian, Andrew S, Rees, Matthew G, Ronan, Melissa M, Roth, Jennifer A, Donovan, Katherine A, Palafox, Marta, Reis-Filho, Jorge S, de Stanchina, Elisa, Fischer, Eric S, Rosen, Neal, Serra, Violeta, Koff, Andrew, Chodera, John D, Gray, Nathanael S, Chandarlapaty, Sarat

Volltext

Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs von Blancafort, Adriana, Giró-Perafita, Ariadna, Oliveras, Glòria, Palomeras, Sònia, Turrado, Carlos, Campuzano, Òscar, Carrión-Salip, Dolors, Massaguer, Anna, Brugada, Ramon, Palafox, Marta, Gómez-Miragaya, Jorge, González-Suárez, Eva, Puig, Teresa

Volltext

RANK Induces Epithelial―Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis von PALAFOX, Marta, FERRER, Irene, TOMETSKO, Mark, BRANSTETTER, Dan, DOUGALL, William C, GONZALEZ-SUAREZ, Eva, PELLEGRINI, Pasquale, VILA, Sergi, HERNANDEZ-ORTEGA, Sara, URRUTICOECHEA, Ander, CLIMEN, Fina, SOLER, Maria Teresa, MUNOZ, Purificación, VINALS, Francesc

Volltext

Modulation of telomere protection by the PI3K/AKT pathway von Méndez-Pertuz, Marinela, Martínez, Paula, Blanco-Aparicio, Carmen, Gómez-Casero, Elena, Belen García, Ana, Martínez-Torrecuadrada, Jorge, Palafox, Marta, Cortés, Javier, Serra, Violeta, Pastor, Joaquin, Blasco, Maria A.

Volltext

The Innate Immune Microenvironment in Metastatic Breast Cancer von Tommasi, Chiara, Pellegrino, Benedetta, Diana, Anna, Palafox Sancez, Marta, Orditura, Michele, Scartozzi, Mario, Musolino, Antonino, Solinas, Cinzia

Volltext

Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts von Gris-Oliver, Albert, Palafox, Marta, Monserrat, Laia, Braso-Maristany, Fara, Odena, Andreu, Sanchez-Guixe, Monica, Ibrahim, Yasir H., Villacampa, Guillermo, Grueso, Judit, Pars, Mireia, Guzman, Marta, Rodriguez, Olga, Bruna, Alejandra, Hirst, Caroline S., Barnicle, Alan, de Bruin, Elza C., Reddy, Avinash, Schiavon, Gaia, Arribas, Joaquin, Mills, Gordon B., Caldas, Carlos, Dienstmann, Rodrigo, Prat, Aleix, Nuciforo, Paolo, Razavi, Pedram, Scaltriti, Maurizio, Turner, Nicholas C., Saura, Cristina, Davies, Barry R., Oliveira, Mafalda, Serra, Violeta

Volltext

Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs von Green, Jennifer L, Okerberg, Eric S, Sejd, Josilyn, Palafox, Marta, Monserrat, Laia, Alemayehu, Senait, Wu, Jiangyue, Sykes, Maria, Aban, Arwin, Serra, Violeta, Nomanbhoy, Tyzoon

Volltext

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models von Rodriguez, María Jimena, Perrone, María Cecilia, Riggio, Marina, Palafox, Marta, Salinas, Valeria, Elia, Andrés, Salgueiro, Natali Daiana, Werbach, Andrea Eugenia, Marks, María Paula, Kauffman, Marcelo A., Vellón, Luciano, Serra, Violeta, Novaro, Virginia

Volltext

Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population von Gómez-Miragaya, Jorge, Palafox, Marta, Paré, Laia, Yoldi, Guillermo, Ferrer, Irene, Vila, Sergi, Galván, Patricia, Pellegrini, Pasquale, Pérez-Montoyo, Hector, Igea, Ana, Muñoz, Purificación, Esteller, Manel, Nebreda, Angel R., Urruticoechea, Ander, Morilla, Idoia, Pernas, Sonia, Climent, Fina, Soler-Monso, María Teresa, Petit, Ana, Serra, Violeta, Prat, Aleix, González-Suárez, Eva

Volltext

Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns von Mateo, Lidia, Duran-Frigola, Miquel, Gris-Oliver, Albert, Palafox, Marta, Scaltriti, Maurizio, Razavi, Pedram, Chandarlapaty, Sarat, Arribas, Joaquin, Bellet, Meritxell, Serra, Violeta, Aloy, Patrick

Volltext

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer von Palafox, Marta, Monserrat, Laia, Bellet, Meritxell, Villacampa, Guillermo, Gonzalez-Perez, Abel, Oliveira, Mafalda, Brasó-Maristany, Fara, Ibrahimi, Nusaibah, Kannan, Srinivasaraghavan, Mina, Leonardo, Herrera-Abreu, Maria Teresa, Òdena, Andreu, Sánchez-Guixé, Mònica, Capelán, Marta, Azaro, Analía, Bruna, Alejandra, Rodríguez, Olga, Guzmán, Marta, Grueso, Judit, Viaplana, Cristina, Hernández, Javier, Su, Faye, Lin, Kui, Clarke, Robert B., Caldas, Carlos, Arribas, Joaquín, Michiels, Stefan, García-Sanz, Alicia, Turner, Nicholas C., Prat, Aleix, Nuciforo, Paolo, Dienstmann, Rodrigo, Verma, Chandra S., Lopez-Bigas, Nuria, Scaltriti, Maurizio, Arnedos, Monica, Saura, Cristina, Serra, Violeta

Volltext

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer von Palafox, Marta, Gonzalez-Perez, Abel, Arribas, Joaquín, López Bigas, Núria, Serra, Violeta

Volltext

MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer von Gawrzak, Sylwia, Rinaldi, Lorenzo, Gregorio, Sara, Arenas, Enrique J., Salvador, Fernando, Urosevic, Jelena, Figueras-Puig, Cristina, Rojo, Federico, del Barco Barrantes, Ivan, Cejalvo, Juan Miguel, Palafox, Marta, Guiu, Marc, Berenguer-Llergo, Antonio, Symeonidi, Aikaterini, Bellmunt, Anna, Kalafatovic, Daniela, Arnal-Estapé, Anna, Fernández, Esther, Müllauer, Barbara, Groeneveld, Rianne, Slobodnyuk, Konstantin, Stephan-Otto Attolini, Camille, Saura, Cristina, Arribas, Joaquín, Cortes, Javier, Rovira, Ana, Muñoz, Montse, Lluch, Ana, Serra, Violeta, Albanell, Joan, Prat, Aleix, Nebreda, Angel R., Benitah, Salvador Aznar, Gomis, Roger R.

Volltext

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance von Serra, Violeta, Wang, Anderson T, Castroviejo-Bermejo, Marta, Polanska, Urszula M, Palafox, Marta, Herencia-Ropero, Andrea, Jones, Gemma N, Lai, Zhongwu, Armenia, Joshua, Michopoulos, Filippos, Llop-Guevara, Alba, Brough, Rachel, Gulati, Aditi, Pettitt, Stephen J, Bulusu, Krishna C, Nikkilä, Jenni, Wilson, Zena, Hughes, Adina, Wijnhoven, Paul W G, Ahmed, Ambar, Bruna, Alejandra, Gris-Oliver, Albert, Guzman, Marta, Rodríguez, Olga, Grueso, Judit, Arribas, Joaquin, Cortés, Javier, Saura, Cristina, Lau, Alan, Critchlow, Susan, Dougherty, Brian, Caldas, Carlos, Mills, Gordon B, Barrett, J Carl, Forment, Josep V, Cadogan, Elaine, Lord, Christopher J, Cruz, Cristina, Balmaña, Judith, O'Connor, Mark J

Volltext

BRCA promoter methylation in triple-negative breast cancer is preserved in xenograft models and represents a potential therapeutic marker for PARP inhibitors von Däster, Kavitha, Hench, Jürgen, Diepenbruck, Maren, Volkmann, Katrin, Rouchon, Adelin, Palafox, Marta, Miragaya, Jorge Gomez, Preca, Bogdan Tiberius, Kurzeder, Christian, Weber, Walter Paul, Bentires-Alj, Mohamed, Soysal, Savas Deniz, Muenst, Simone

Volltext

MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer von Gawrzak, Sylwia, Rinaldi, Lorenzo, Gregorio, Sara, Arenas, Enrique J., Salvador, Fernando, Urosevic, Jelena, Figueras-Puig, Cristina, Rojo, Federico, del Barco Barrantes, Ivan, Cejalvo, Juan Miguel, Palafox, Marta, Guiu, Marc, Berenguer-Llergo, Antonio, Symeonidi, Aikaterini, Bellmunt, Anna, Kalafatovic, Daniela, Arnal-Estapé, Anna, Fernández, Esther, Müllauer, Barbara, Groeneveld, Rianne, Slobodnyuk, Konstantin, Stephan-Otto Attolini, Camille, Saura, Cristina, Arribas, Joaquín, Cortes, Javier, Rovira, Ana, Muñoz, Montse, Lluch, Ana, Serra, Violeta, Albanell, Joan, Prat, Aleix, Nebreda, Angel R., Benitah, Salvador Aznar, Gomis, Roger R.

Volltext

Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies von Saei, Azad, Palafox, Marta, Benoukraf, Touati, Kumari, Nishi, Jaynes, Patrick William, Iyengar, Prasanna Vasudevan, Muñoz-Couselo, Eva, Nuciforo, Paolo, Cortés, Javier, Nötzel, Christopher, Kumarakulasinghe, Nesaretnam Barr, Richard, John Lalith Charles, Bin Adam Isa, Zul Fazreen, Pang, Brendan, Guzman, Marta, Siqin, Zhou, Yang, Henry, Tam, Wai Leong, Serra, Violeta, Eichhorn, Pieter Johan Adam

Volltext

Abstract 1282: Overcoming resistance to inhibitors of CDK4/6 and BET in estrogen receptor-positive breast cancer von Cosín, Marc, Tian, Tian, Oliveros, Winona, Kharenko, Olesya A., van der Horst, Edward H., Patel, Reena G., Calosing, Cyrus, Campeau, Eric, Jahagirdar, Ravi, Lakhotia, Sanjay, Melé, Marta, Palafox, Marta, Arribas, Joaquín, Oliveira, Mafalda, Saura, Cristina, Serra, Violeta, Peiro, Sandra

Volltext

Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer von Palafox, Marta, Monserrat, Laia, Bellet, Meritxell, Villacampa, Guillermo, Gonzalez-Perez, Abel, Oliveira, Mafalda, Brasó-Maristany, Fara, Ibrahimi, Nusaibah, Kannan, Srinivasaraghavan, Mina, Leonardo, Herrera-Abreu, Maria Teresa, Òdena, Andreu, Sánchez-Guixé, Mònica, Capelán, Marta, Azaro, Analía, Bruna, Alejandra, Rodríguez, Olga, Guzmán, Marta, Grueso, Judit, Viaplana, Cristina, Hernández, Javier, Su, Faye, Lin, Kui, Clarke, Robert B., Caldas, Carlos, Arribas, Joaquín, Michiels, Stefan, García-Sanz, Alicia, Turner, Nicholas C., Prat, Aleix, Nuciforo, Paolo, Dienstmann, Rodrigo, Verma, Chandra S., Lopez-Bigas, Nuria, Scaltriti, Maurizio, Arnedos, Monica, Saura, Cristina, Serra, Violeta

Volltext